Price
No data yet.
Social Signal Score
Revenue
$1.64B+117.30%Company Profile
- CEO
- Ludwig Hantson
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,837
- Beta
- 1.26
- Country
- US
Financials
Revenue
$1.64B+117.3%Net Income
$636.00M+453.3%EBITDA
$705.30M+141.9%Free Cash Flow
$507.40M+186.5%EPS (diluted)
$2.86+460.8%Shares Outstanding (diluted)
222.60M-1.4%Operating Expenses
$632.00MCash & Debt
$3.47BReturn of Capital
$0.00Revenue by Segment (annual)
$6.07BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2020 | $6.07B | $603.40M | $2.75 |
| 2019 | $4.99B | $2.40B | $10.70 |
| 2018 | $4.13B | $77.60M | $0.35 |
| 2017 | $3.55B | $443.30M | $1.98 |
| 2016 | $3.08B | $399.00M | $1.78 |
| 2015 | $2.60B | $144.38M | $0.68 |
| 2014 | $2.23B | $656.91M | $3.32 |
| 2013 | $1.55B | $252.90M | $1.29 |
| 2012 | $1.13B | $254.82M | $1.34 |
| 2011 | $783.43M | $175.31M | $0.96 |
| 2010 | $540.96M | $97.03M | $0.54 |
| 2009 | $386.80M | $295.17M | $1.73 |
| 2008 | $259.10M | $33.15M | $0.21 |
| 2007 | $72.04M | $-92.29M | $-0.64 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $4.05
- Implied price
- $230.65
- Return from $182.50
- 4.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $114.67 — -37.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 39 | 48 | 57 | 66 | 75 |
|---|---|---|---|---|---|
| -2.0% | -11.9% | -8.1% | -4.9% | -2.1% | 0.5% |
| 3.0% | -7.4% | -3.4% | -0.1% | 2.9% | 5.6% |
| 8.0% | -2.9% | 1.3% | 4.8% | 7.9% | 10.7% |
| 13.0% | 1.6% | 5.9% | 9.6% | 12.9% | 15.8% |
| 18.0% | 6.1% | 10.6% | 14.5% | 17.9% | 21.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
107Social Signal Score
Mentions (1)
- Newsseekingalpha.com·1d ago·Neutral
…ng Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy' Monopar Therapeutics (MNPR) remains a "Strong Buy," driven by exclusive license rights to ALXN1840 for Wilson disease and ongoing radiotherapeutic development. Completion of the rolling NDA for ALXN1840 in the coming months is a major catalyst, with potential FDA approval and Priority Review Voucher upside. ALXN1840 demonstrated statistically significant efficacy in phase 3, showing 3x copper mobilization over placebo an…
View source ↗
Earnings
Typical surprise +15.6% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Apr 30$3.52 vs $3.16beat
- Thu, Feb 4$2.96 vs $2.56beat
- Thu, Oct 29$3.24 vs $2.60beat
- Thu, Jul 30$3.11 vs $2.59beat
- Wed, May 6$3.22 vs $2.71beat
- Thu, Jan 30$2.71 vs $2.60beat
Estimates and results for ALXN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ALXN officers and directors.
- Bought
- —
- Sold
- $3.8m
0 trades
3 trades
- Bazarko Danielsold
- Bazarko Danielsold
- Bazarko Danielsold
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.